Articles for author: Russ Cohen

Russ Cohen

The Potential of High-Growth Stocks to Reach $1 Trillion in a Decade

Even though market capitalization shouldn’t influence a company’s growth, the milestone of reaching a trillion-dollar market cap has become a symbol of prestige and success since Apple first achieved this feat in 2018. The market has pushed more companies toward this threshold, changing the way they are viewed once they achieve it. It’s akin to ...

Russ Cohen

Is Nvidia Stock a Buy in 2024? Is Nvidia Stock a Buy in 2024?

Investors have witnessed Nvidia’s meteoric rise over the past year, with shares soaring about 230%. The company’s reign as the dominant force in AI chips and its potential for growth in the PC market make it an intriguing investment opportunity. Nvidia’s Unassailable Position in AI Nvidia has firmly secured an estimated 90% market share in ...

Russ Cohen

Investor’s Guide: Microsoft Emerges as Top AI Stock to Watch Investor’s Guide: Microsoft Emerges as Top AI Stock to Watch

Over the past year, Nvidia (NASDAQ: NVDA) has been the talk of the town and one of the stock market’s best-performing large companies. The company designs the kind of advanced graphics processing unit (GPU) technology needed for artificial intelligence (AI). As a result, the GPU leader’s revenue and earnings have been skyrocketing. Sales surged 206% ...

Russ Cohen

Amazon Seeks to Revolutionize Streaming Advertising Amazon Seeks to Revolutionize Streaming Advertising

Amazon.Com Inc’s introduction of ads on Prime Video will likely impact the crowded U.S. streaming market significantly. As the third-largest digital ad seller globally, Amazon’s $12 billion ad revenue in the third quarter marks a 26% increase from the previous year. Their vast customer data offers a unique edge in targeted advertising. Analysts see $6.6 ...

Russ Cohen

Understanding the Recent Legal Setback for Genmab and Its Implications for Investors Understanding the Recent Legal Setback for Genmab and Its Implications for Investors

Monday brought significant legal news for Genmab A/S (NASDAQ: GMAB) as an appeal arbitrator dismissed the biotech company’s bid for additional milestone and royalty payments related to Darzalex (daratumumab). In an SEC filing, Genmab revealed that the appeal arbitrator in its second arbitration under the license agreement with Janssen Biotech Inc, Johnson & Johnson’s (NYSE: ...

Russ Cohen

PACCAR Quarterly Earnings Overview

PACCAR PCAR, a trucking giant, will unveil its fourth-quarter 2023 results tomorrow, before the stock market opens. Analysts predict earnings per share of $2.20 and revenues of $8.18 billion for the quarter. The consensus estimate for PACCAR’s earnings per share has risen by 3 cents in the past seven days, indicating a potential 25% growth ...

Russ Cohen

Alibaba (BABA) Stock: Evaluating Wall Street Analyst Recommendations Alibaba (BABA) Stock: Evaluating Wall Street Analyst Recommendations

Investors frequently turn to analyst recommendations when considering stock transactions, but how much weight should one give these endorsements? Let’s explore Wall Street’s take on Alibaba (BABA) and delve into the reliability of brokerage endorsements as well as strategies for leveraging them. Analyst Recommendations for Alibaba Alibaba currently boasts an average brokerage recommendation (ABR) of ...